Clinical Trials
33 trialsMMR Status Modulates the Predictive Value of Lymphatic Invasion for Lymph Node Metastasis in Gastric Cancer
Shanghai Zhongshan Hospital
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors
University of Pittsburgh
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Sun Yat-sen University
PICC-3
Sun Yat-sen University
LYNX-EYE
San Raffaele University
SJFAMILY
St. Jude Children's Research Hospital
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RIPAF
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
BEACON
San Raffaele University
TORCH-OPTIMA
Fudan University
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
University of Cincinnati
CATALIS
Shanghai Zhongshan Hospital
IMMUNE-SAVE
Women's Hospital School Of Medicine Zhejiang University
PREDI-LYNCH
UNICANCER
Pre-CATALIS
Shanghai Zhongshan Hospital
PICC
Sun Yat-sen University
NITDC
Peking Union Medical College Hospital
ANTONIO
AIO-Studien-gGmbH
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
CoRDS
Sanford Health
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome
WellSpan Health
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
PROGRESS
Massachusetts General Hospital
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Peking University People's Hospital
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
West China Hospital
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
The Hospital for Sick Children
REGOMUNE
Institut Bergonié
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Sun Yat-sen University
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center